

ongoing trials - trial from www.clinicaltrials.gov

A Study to Compare US Marketed Pancrelipase Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis. - Phase 4 - Not yet recruiting

Code: NCT03924947 **Year:** 2019 **Date:** May 10, 2019

Author: AbbVie

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Participants

Cystic Fibrosis - 12 Years and older (Child, Adult, Older Adult)

Interventions

Drug: Pancrelipase

Outcome measures

Coefficient of Fat Absorption (CFA)|Stool fat|Coefficient of Nitrogen Absorption (CNA)|Stool weight

<https://ClinicalTrials.gov/show/NCT03924947>

Keywords

Adolescent; Adult; Child; Enteric-Coated; Gastrointestinal Agents; Gastrointestinal Diseases; Microspheres; pharmacological_intervention; Pancreas insufficiency; Pancreatic Diseases; Pancreatic Enzyme Replacement Therapy; Supplementation; Malabsorption; Nutrition Disorders; Home; Pancrelipase;